In a patient with recent acute myocardial infarction who now has a clinically significant gastrointestinal bleed, should I hold the P2Y12 inhibitor and therapeutic anticoagulation, continue aspirin, and when should each antithrombotic be restarted?

Management of Antiplatelet and Anticoagulant Therapy in Post-MI Patients with GI Bleeding

Immediate Management During Active Bleeding

When a post-MI patient develops clinically significant GI bleeding, hold the P2Y12 inhibitor and all parenteral anticoagulants immediately, but continue aspirin 75-100 mg daily if hemodynamically stable. 1, 2, 3

Which Agents to Stop

• Discontinue the P2Y12 inhibitor (ticagrelor, prasugrel, or clopidogrel) during active bleeding because these agents produce potent platelet inhibition that substantially increases bleeding risk. 2, 4
• Stop all parenteral anticoagulants (unfractionated heparin, enoxaparin, fondaparinux, bivalirudin) while active bleeding persists. 2
• Continue aspirin 75-100 mg daily if the patient is hemodynamically stable, as aspirin monotherapy provides a more favorable balance between ischemic protection and bleeding complications compared to dual antiplatelet therapy. 2, 4

Critical Distinction: Which P2Y12 Inhibitor to Hold First

• Ticagrelor and prasugrel should be the first agents held when bleeding necessitates de-escalation because they produce more rapid and potent platelet inhibition than clopidogrel, resulting in higher bleeding rates. 1, 5
• If the patient was on clopidogrel, holding it still provides meaningful bleeding risk reduction while aspirin monotherapy maintains baseline ischemic protection. 2, 4

Gastric Protection Strategy (Mandatory)

Initiate a proton pump inhibitor immediately in all patients requiring antithrombotic therapy after GI bleeding—this is a Class I recommendation. 1, 2, 3

• Prescribe pantoprazole 40 mg once daily or omeprazole 20 mg once daily as standard dosing for most patients. 1, 2
• Continue PPI therapy indefinitely for as long as the patient remains on antiplatelet agents, since prior upper GI bleeding is the strongest predictor of recurrence. 1, 2
• Do not delay PPI initiation—start gastro-protection immediately rather than waiting for recurrent bleeding. 2

When to Resume P2Y12 Inhibitor

Restart the P2Y12 inhibitor as soon as hemostasis is achieved and the risk of recurrent cardiac events outweighs the risk of further bleeding, typically after endoscopic control of the bleed. 1, 2, 4

Timing Algorithm

• If endoscopic hemostasis is confirmed (e.g., clipped ulcer, cauterized vessel), resume the P2Y12 inhibitor on the same day or within 24 hours. 1, 4
• If the bleeding source cannot be definitively controlled or high-risk stigmata persist (visible vessel, adherent clot), delay P2Y12 inhibitor resumption for 3-5 days while continuing aspirin and PPI. 4
• Never delay beyond 7 days, as prolonged interruption of dual antiplatelet therapy dramatically increases the risk of stent thrombosis, myocardial infarction, and death—particularly within the first 30 days after stent placement. 1, 3

Which P2Y12 Inhibitor to Resume

• Switch to clopidogrel 75 mg daily (with a 600 mg loading dose if not previously loaded) when resuming therapy after GI bleeding, because clopidogrel has the most favorable bleeding profile among P2Y12 inhibitors. 2, 4, 5
• Do not resume ticagrelor or prasugrel in patients who have experienced GI bleeding, as these agents carry substantially higher bleeding risk (ticagrelor RR 1.36, prasugrel RR 2.11 compared to clopidogrel). 5
• If the patient was initially on ticagrelor or prasugrel, this represents an appropriate clinical scenario to de-escalate to clopidogrel for the remainder of the 12-month DAPT course. 2, 5

Duration of Dual Antiplatelet Therapy After Bleeding

Complete a total of 12 months of DAPT (aspirin + clopidogrel) from the time of the original MI, unless bleeding risk clearly outweighs benefit. 1, 2, 3

• For patients with high bleeding risk (PRECISE-DAPT score ≥25), consider shortening DAPT to 6 months total, but never discontinue within the first 30 days after stent placement. 1, 3
• After completing the minimum DAPT duration, transition to aspirin 75-100 mg daily as lifelong monotherapy. 6, 1

Management of Anticoagulation

If the patient requires therapeutic anticoagulation (e.g., atrial fibrillation, mechanical valve), resume anticoagulation after hemostasis is confirmed, but modify the antithrombotic regimen. 6, 1

• Discontinue aspirin 1-4 weeks after the bleeding episode and continue clopidogrel 75 mg daily plus the oral anticoagulant (dual therapy), as this provides a markedly lower bleeding risk than triple therapy. 6, 1, 5
• Prefer a direct oral anticoagulant (DOAC) over warfarin when resuming anticoagulation, as DOACs are associated with lower GI bleeding rates. 6

Reversal Agents: What NOT to Do

Do not administer reversal agents or platelet transfusions for antiplatelet-associated bleeding unless the patient has life-threatening hemorrhage that cannot be controlled by other measures. 4

• For patients on warfarin with GI bleeding, do not give fresh frozen plasma or vitamin K; if reversal is absolutely necessary, use prothrombin complex concentrate (PCC). 4
• For patients on DOACs with GI bleeding, do not administer PCC, idarucizumab (for dabigatran), or andexanet alfa (for rivaroxaban/apixaban). 4
• For patients on antiplatelet agents, do not give platelet transfusions, as these do not improve outcomes and may paradoxically increase thrombotic risk. 4

Common Pitfalls to Avoid

• Do not hold aspirin in hemodynamically stable patients—aspirin monotherapy should be continued during active GI bleeding to prevent stent thrombosis and recurrent MI. 2, 4
• Do not resume ticagrelor or prasugrel after GI bleeding—switch to clopidogrel for the remainder of the DAPT course. 2, 5
• Do not omit PPI therapy—this simple intervention significantly reduces recurrent GI bleeding and is mandatory for all patients on antithrombotic therapy. 1, 2, 3
• Do not delay P2Y12 inhibitor resumption beyond 7 days—prolonged interruption markedly increases stent thrombosis risk, particularly within the first month after MI. 1, 3
• Do not restart aspirin at high doses (325 mg)—low-dose aspirin (75-100 mg) provides equivalent efficacy with lower bleeding risk. 1, 2, 3